Carisma to Withdraw from Nasdaq and Terminate SEC Registration

Written by Emily J. Thompson, Senior Investment Analyst

CARM%

Source: Yahoo Finance

Updated: Dec 05 2025

0mins

Source: Yahoo Finance

Delisting Announcement: Carisma Therapeutics Inc. has announced its intention to voluntarily delist its common stock from Nasdaq and deregister under the Securities Exchange Act of 1934, following a determination of noncompliance with Nasdaq listing requirements.
Trading Transition: The company's common stock was suspended from trading on Nasdaq on October 13, 2025, and has since begun trading on the OTCID market under the symbol "CARM."
Timeline for Delisting: Carisma plans to file a Form 25 with the SEC around December 15, 2025, with the formal delisting expected to take effect by December 25, 2025, followed by a Form 15 filing to suspend reporting obligations.
Company Background: Carisma Therapeutics is a biotechnology firm focused on macrophage engineering for treating serious diseases, and it is currently winding down its operations.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.